Gilead Sciences Inc. (GILD)
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?
GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend investors to wait and watch for now.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
EU regulator backs Gilead's twice-yearly injection for HIV prevention
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents, the drugmaker said on Friday.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Gilead Sciences (GILD) Fell More Than Broader Market
Gilead Sciences (GILD) closed at $109.06 in the latest trading session, marking a -2.7% move from the prior day.
WHO recommends Gilead's twice-yearly injection for HIV prevention
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.
